After the inspection found problems this year, an FDA spokesperson said the agency can only discuss potential or ongoing compliance matters with the company involved. Among the most serious violations outlined in the FDA letter to Glenmark was the company's failure to promptly test pills to ensure they dissolve properly during their normal shelf life, the subject of ProPublica's investigation last year. Companies hold on to samples of pills from batches sold to U.S. customers and test them periodically until they reach their expiration date. Medicines that don't dissolve properly can cause perilous swings in dosing. This flaw is what made Glenmark's potassium chloride pills potentially deadly since high potassium levels can stop the heart, according to the June 2024 recall notice. Glenmark's backlogged testing "was overdue by 3 months or longer for a large proportion of your samples," the FDA wrote in the warning letter.